Differential regulation of Th1/Th2 in relevant tissues for sepsis pathogenesis with a Limulus anti-LPS factor-derived peptide increases survival in Gram-positive sepsis

International Immunopharmacology

Volumn 4, Issue 10-11, 2004, Pages 1343-1351

  Vallespi, Maribel G ^a   Colas, M ^a   Garay, H ^a   Reyes, O ^a   Arana M J ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Cytokines; Gram positive sepsis; Immunomodulation; Limulus anti LPS factor derived peptide; Prophylaxis; Th1 Th2 response

Indexed keywords

CYTOKINE; HISTIDYLTYROSYLARGINYLISOLEUCYLLYSYLPROLYLTHREONYLPHENYLALANYLARGINYL ARGINYLLEUCYLLYSYLTRYPTOPHYLLYSYLTYROSYLLYSYLGLYCYLLYSYLPHENYLALANYLTRYPTOPHAN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; GRAM POSITIVE BACTERIUM; INFLAMMATION; LIMULUS; LIVER; LIVER INJURY; LIVER SINUSOID; LUNG; LUNG INJURY; MORPHOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEPSIS; STAPHYLOCOCCUS HAEMOLYTICUS; SURVIVAL; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ANIMALS; ANTI-INFECTIVE AGENTS; CYTOKINES; GENE EXPRESSION REGULATION; INVERTEBRATE HORMONES; LIVER; LUNG; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; RNA, MESSENGER; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS HAEMOLYTICUS; SURVIVAL RATE; TH1 CELLS; TH2 CELLS; TIME FACTORS;

EID: 4143054852     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2004.05.019     Document Type: Article

References (26)

1. Poll T. Immunotherapy of sepsis. Lancet. 1:2001;165-174
2. Poll T., Deventer S.J. Cytokines and anticytokines in the pathogenesis of sepsis. Infect. Dis. Clin. North Am. 13:1999;413-426
3. Hernández M.E., Ferrer N.F., López M.L., Ramos M.J. Tratamiento con Azlocillin y amikacina en sepsis neonatal por Staphylococcus haemolyticus multiresistente. Rev. Cuba. Pediatr. 72:2000;60-64
4. Martin G.S., Bernard G.R. Airway and lung in sepsis. Intensive Care Med. 27:2001;63-79
5. Menrrifield R.B. Solid phase peptide synthesis. J. Am. Chem. Soc. 85:1963;2149-2154
6. Vallespi M.G., Alvarez-Obregón J.C., Rodríguez-Alonso I., Montero T., Garay H., Reyes O., et al. A Limulus anti-LPS factor-derived peptide modulates cytokine gene expression and promotes resolution of bacterial acute infection in mice. Intern. Immunopharmacol. 3:2003;247-256
7. Grohmann U., Snick J., Campanile F., Silla S., Giampietri A., Vacca C., et al. IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-α, IL-12, and IFN-γ, and induction of IL-10. J. Immunol. 164:2000;4197-4203
8. Bochud P.-Y., Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. Br. Med. J. 326:2003;262-266
9. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. New Engl. J. Med. 348:2003;138-150
10. Volk H.D., Reinke P., Döcke W.D. Clinical aspects: from systemic inflammation to immunoparalysis. Chem. Immunol. 74:2000;162-177
11. Volk H.D., Asadullah K., Gallagher G., Sabat R., Grütz G. IL-10 and its homologs: important immune mediators and emerging immunotherapeutic agents. Trends Immunol. 22:2001;414-417
12. Poll T., Marchant A., Buurman W.A., Berman L., Keogh C.V., Lazarus D.D., et al. Endogenous IL-10 protects mice from death during septic peritonitis. J. Immunol. 155:1995;5397
13. Kato T., Murata A., Ishida H., Toda H., Tanaka N., Hayashida H., et al. Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob. Agents Chemother. 39:1995;1336
14. Mehrad B., Standiford T.J. Role of cytokines in pulmonary antimicrobial host defense. Immunol. Res. 20:1999;15-27
15. Strieter R.M., Belperio J.A., Keane M.P. Host innate defenses in the lung: the role of cytokines. Curr. Opin. Infect. Dis. 16:2003;193-198
16. Sewnath M.E., Olszyna D.P., Birjmohun R. IL-10-deficient mice demonstrate multiorgan failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J. Immunol. 166:2001;6323-6331
17. Latifi S.Q., O'Riordan M.A., Levine A.D. Interleukin-10 controls the onset of irreversible septic shock. Infect. Immun. 70:2002;4441-4446
18. Higgins S.C., Lavelle E.C., Chantelle M.C., Keogh B., McNeela E., Byrne P., et al. Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J. Immunol. 171:2003;3119-3127
19. Matute-Bello G., Frevert C.W., Kajikawa O., Skerrett S.J. Septic shock and acute lung injury in rabbits with peritonitis: failure of the neutrophil response to localized infection. Am. J. Respir. Crit. Care Med. 163:2001;234-243
20. Ayala A., Deol Z.K., Lehman D.L., Herdon C.D., Chaudry I.H. Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/IFN-γ release while increasing IL-4/IL-10 production. J. Surg. Res. 56:1994;579-585
21. Lesur O., Kokis A., Hermans C., Fülöp T., Bernard A., Lane D. Interleukin-2 involvement in early acute respiratory distress syndrome: relationship with polymorphonuclear neutrophil apoptosis and patient survival. Crit. Care Med. 28:2000;3814-3822
22. Granucci F., Feau S., Angeli V., Trottein F., Ricciardi-Castagnoli R. Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming. J. Immunol. 170:2003;5075-5081
23. Jankovic D., Liu Z., Gause W.C. Th1-and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol. 22:2001;450-457
24. Brewington R., Chatterji M., Zoubine M., Miranda R.N., Norimatsu M., Shnyra A. IFN-γ-independent autocrine cytokine regulatory mechanism in reprogramming of macrophage responses to bacterial lipopolysaccharide. J. Immunol. 167:2001;392-398
25. Yamaguchi T., Hirakata Y., Izumikawa K., Miyazaki Y., Maesaki S., Tomono K., et al. Prolonged survival of mice with Pseudomonas aeruginosa-induced sepsis by rIL-12 modulation of IL-12 and IFN-γ J. Med. Microbiol. 49:2000;701-707
26. Bone R.C. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome and multiple organ dysfunction syndrome. Ann. Intern. Med. 125:1996;680-687